Last reviewed · How we verify
Norpace Cr (DISOPYRAMIDE)
Norpace Cr (Disopyramide) is an antiarrhythmic medication originally developed by GD Searle LLC and currently owned by Pfizer. It is a small molecule that targets the histamine H1 receptor to treat ventricular arrhythmia. Disopyramide is off-patent, with multiple generic manufacturers available. The medication has a half-life of 7.0 hours and bioavailability of 83%. It was FDA-approved in 1977 for the treatment of ventricular arrhythmia.
At a glance
| Generic name | DISOPYRAMIDE |
|---|---|
| Sponsor | Pfizer |
| Drug class | Antiarrhythmic |
| Target | Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1977 |
Approved indications
- Ventricular arrhythmia
Common side effects
- Urinary retention
- Dry mouth
- Urinary hesitancy
- Constipation
- Blurred vision
- Dry nose/eyes/throat
- Urinary frequency and urgency
- Nausea
- Pain/bloating/gas
- Dizziness
- General fatigue/muscle weakness
- Headache
Drug interactions
- High Risk QT Prolonging Agents
- ciprofloxacin
- esmolol
- gatifloxacin
- gemifloxacin
- labetalol
- levofloxacin
- metoprolol
- moxifloxacin
- nadolol
- nalidixic acid
- norfloxacin
Key clinical trials
- Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy (PHASE2)
- A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
- A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy (PHASE2)
- Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation (CAPTAF Trial) (NA)
- Evaluate the Efficacy of Disopyramide Therapy in Hypertrophic Obstructive Cardiomyopathy Patients (NA)
- Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) (PHASE3)
- AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Norpace Cr CI brief — competitive landscape report
- Norpace Cr updates RSS · CI watch RSS
- Pfizer portfolio CI